This site is intended for healthcare professionals

Regulatory approval of Dysval for the treatment of tardive dyskinesia in Japan.

Read time: 1 mins
Published:29th Mar 2022

Neurocrine Biosciences, Inc. announced that its collaboration partner, Mitsubishi Tanabe Pharma Corporation (MTPC), obtained regulatory approval of Dysval capsules 40 mg (valbenazine) for the treatment of tardive dyskinesia from the Japanese Ministry of Health, Labour and Welfare on March 28, 2022.

In March 2015, Neurocrine Biosciences entered into a collaboration and license agreement with MTPC for the development and commercialization of valbenazine capsules for movement disorders in Japan and other select Asian markets. Under the terms of the agreement, MTPC is responsible for all development, manufacturing and commercialization costs of valbenazine in such markets.

Condition: Tardive Dyskinesia
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.